

# **EXHIBIT B**

1:15-cv-07488-CM-RWL

## Forest's Phase 2 Exhibit List

Trial Ex. No.	Dep. Ex. #	Beg Bates	End Bates	Date	Doc Description	Objections	Includes Electronic File(s)
DTX-025	Snyder Ex. 6	N/A	N/A	10/6/2017	Document: Declaration of Julie Snyder	802	
DTX-027	Benton (Smith Drug) Ex. 24	N/A	N/A	11/30/2015	Document: NYAG Settlement Agreement	Preserving objections for the record, but understand they are admissible under the Motion in Limine Ruling: 802, 103, 602, 701, 402, 403	
DTX-028	Devlin Ex. 34	N/A	N/A	11/25/2015	Press Release: "A.G. Schneiderman Announces Resolution Of Lawsuit That Protected Alzheimer's Patients From Anticompetitive Tactic Aimed At Maintaining Higher Drug Prices"	Preserving objections for the record, but understand they are admissible under the Motion in Limine Ruling: 802, HS w/in HS, 402, 403, 602	
DTX-035	PX76 (NYAG Hearing)	FRX-AT-01752159	FRX-AT-01752159	11/9/2014	Excel: "PX76 - Copy of FRX-NY-01639146 (full Namenda model).xlsx"		Yes
DTX-036		FRX-AT-01612936	FRX-AT-01612940	10/14/2013	Email: "RE: NamendaTransitionPlan.ppt"		Yes
DTX-037		FRX-AT-00952898	FRX-AT-00952900	10/21/2013	Email: "RE: XR erosion assumptions"		Yes
DTX-039		FRX-AT-01608704	FRX-AT-01608706	10/16/2013	Email: "Updated Namenda model"		Yes
DTX-042	Berndt Ex. 16	FRX-AT-01639171	FRX-AT-01639171	12/23/2013	Excel: "Namenda production forecast_10292013_Flex XR LOE 1201213 July Carolyn"		Yes
DTX-043	Lamb Ex. 16 Lamb Ex. 17	FRX-AT-01639598	FRX-AT-01639598	10/10/2013	Excel: "Namenda production forecast_10082013 v3 LOE Jan17.xls"		Yes
DTX-044	Berndt Ex. 17	FRX-AT-03729066	FRX-AT-03729066	1/29/2014	Excel: "Namenda production forecast_10292013_Flex XR LOE 12914.xlsx"		Yes
DTX-045		FRX-AT-03732735	FRX-AT-03732742	1/9/2014	PowerPoint: "Namenda Franchise"		
DTX-048	Harper (NYAG) Ex. 11 Reisberg (NYAG) Ex. 4 DX371 (NYAG Hearing)	FRX-AT-01765949	FRX-AT-01765950	6/10/2014	Press Release: "Forest Laboratories Announces Intention to Continue Marketing Both NAMENDA TABLETS and Once-Daily NAMENDA XR Into the Fall of 2014"		
DTX-049		FRX-AT-03694184	FRX-AT-03694186	1/6/2015	Email: "A Message from Bill Meury - Launch of Namenda XR Direct-to-Consumer Advertising Campaign"		
DTX-097		FRX-AT-01595330	FRX-AT-01595333	6/26/2013	Email: "RE: Disconnect on market share build for XR forecast vs model"		Yes
DTX-098		FRX-AT-01595850	FRX-AT-01595859	9/13/2013	Email: "RE: MDX-8704 (NAMENDA XR/donepezil) Forecast"		Yes
DTX-105		FRX-AT-01611804	FRX-AT-01611806	2/26/2014	Email: "FW: latest forecast"		Yes
DTX-106		FRX-AT-01613385	FRX-AT-01613386	12/19/2013	Email: "MDX Namenda Working Forecast LE2 090513 FINAL.xls"		Yes
DTX-112		FRX-AT-01619280	FRX-AT-01619281	11/8/2013	Email: "Namenda production forecast_10152013_Flex XR LOE.xlsx"		
DTX-115		FRX-AT-01639600	FRX-AT-01639600	11/22/2013	Excel: "Namenda production forecast_10152013_Flex XR LOE.xlsx"		

1:15-cv-07488-CM-RWL

## Forest's Phase 2 Exhibit List

Trial Ex. No.	Dep. Ex. #	Beg Bates	End Bates	Date	Doc Description	Objections	Includes Electronic File(s)
DTX-117		FRX-AT-01639602	FRX-AT-01639602	10/17/2013	Excel: "Namenda production forecast_10082013 v3 LOE Apr18.xls"		Yes
DTX-120		FRX-AT-01655249	FRX-AT-01655251	11/26/2013	Email: "Re: Can you forward me the most current Namenda model?"		
DTX-122		FRX-AT-01656853	FRX-AT-01656854	11/8/2013	Email: "FW: Namenda Royalty Model"		Yes
DTX-127		FRX-AT-01671051	FRX-AT-01671051	10/15/2013	Excel: "Namenda Working Forecast LE3 100213.xls"		Yes
DTX-129		FRX-AT-01694562	FRX-AT-01694564	11/20/2013	Document: "Namenda XR- Key Topline Findings for Caregiver Survey"	802 and Hearsay within Hearsay	
DTX-131	Lah (NYAG) Ex. 23	FRX-AT-01726854	FRX-AT-01726854	10/2/2014	Document: Query Results from Emory Clinical Data Warehouse		
DTX-134	Lah (NYAG) Ex. 3	FRX-AT-01726984	FRX-AT-01726984	3/13/2014	Email: "Re: Namenda"	802	
DTX-142	Stewart (NYAG) Ex. 1	FRX-AT-01733383	FRX-AT-01733385	10/21/2014	Document: Declaration of Robert Stewart	402, 403, 701, 802	
DTX-150		FRX-AT-01736857	FRX-AT-01736874	10/14/2013	Document: "Physician Survey Final Results Report"	802 and Hearsay within Hearsay	
DTX-155		FRX-AT-01746817	FRX-AT-01746824	10/17/2014	Document: Declaration of Dr. Bruce D. Kohrman, M.D.	402, 403, 602, 702, 802	
DTX-163	Harper (Mylan-NYAG) Ex. 12	FRX-AT-01750242	FRX-AT-01750244	2/14/2014	Press Release: "Forest Laboratories to Discontinue NAMENDA Tablets, Focus on Once-Daily NAMENDA XR"		
DTX-167	Meury (NYAG) Ex. 1 DX720 (NYAG Hearing)	FRX-AT-01771984	FRX-AT-01772075	10/21/2014	Document: Declaration of William J. Meury	402, 403, 602, 701, 802, CE	
DTX-169	Devlin (NYAG) Ex. 3  Devlin Ex. 16	FRX-AT-01779417	FRX-AT-01779419	10/18/2013	Email: "RE: Namenda XR Transition Project Team"		
DTX-172		FRX-AT-01779996	FRX-AT-01780023	10/20/2014	Document: Declaration of Alan R. Jacobs	402, 403, 602, 702, 802, CE	
DTX-174		FRX-AT-01781301	FRX-AT-01781338	10/20/2014	Document: Declaration of Barry Rovner, M.D.	402, 403, 602, 702, 802, CE	
DTX-178		FRX-AT-01813893	FRX-AT-01813893	11/25/2013	Excel: "Namenda production forecast_10292013_Flex XR LOE 112513MAX.xlsx"		Yes
DTX-179		FRX-AT-01819305	FRX-AT-01819307	11/6/2014	Email: "Re: Namenda XR Supply Update"		
DTX-190		FRX-AT-01904310	FRX-AT-01904337	12/31/2012	Email: "Namenda persistency 2012 - for your review/need to circulate to upper mgmt"	802	
DTX-192		FRX-AT-01915218	FRX-AT-01915233	10/23/2013	Presentation: "Namenda Franchise Physician Survey n=159 Final Results for Open-Ends 10-23-2013.pptx"	802 and Hearsay within Hearsay	
DTX-243		FRX-AT-03570707	FRX-AT-03570721	10/7/2014	Email: "Namenda Rejection and Reversal Data - August 2014"		
DTX-267	Cremieux Ex. 1 Fowdur Ex. 23	FRX-AT-03670529	FRX-AT-03670532	12/11/2014	Email: "Actavis Confirms District Court Ruling to Require Continued Distribution of NAMENDA IR"		
DTX-268		FRX-AT-03671360	FRX-AT-03671364	5/22/2015	Email: "Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR"		
DTX-275		FRX-AT-03727191	FRX-AT-03727191	12/6/2013	Excel: "Namenda production forecast_10292013_Flex XR LOE 120213.xlsx"		Yes
DTX-276		FRX-AT-03727529	FRX-AT-03727529	12/17/2013	Excel: "Namenda production forecast_10292013_Flex XR LOE 120213 July.xlsx"		Yes

1:15-cv-07488-CM-RWL

## Forest's Phase 2 Exhibit List

Trial Ex. No.	Dep. Ex. #	Beg Bates	End Bates	Date	Doc Description	Objections	Includes Electronic File(s)
DTX-277		FRX-AT-03727794	FRX-AT-03727794	1/7/2014	Excel: "Namenda production forecast_10292013_Flex XR LOE 120213 SepMAX.xlsx"		Yes
DTX-278		FRX-AT-03727831	FRX-AT-03727831	1/9/2014	Excel: "Namenda production forecast_10292013_Flex XR LOE 120213 SepLOW.xlsx"		Yes
DTX-281		FRX-AT-03731393	FRX-AT-03731393	3/9/2014	Excel: "Namenda production forecast_10292013_Flex XR LOE 120213 disrupt10.xlsx"		Yes
DTX-283		FRX-AT-03744160	FRX-AT-03744161	1/12/2015	Email: "FW: TEST - Information about NAMENDA (memantine HCl) tablets and NAMENDA XR (memantine HCl) extended-release capsules"		
DTX-286		FRX-AT-03793252	FRX-AT-03793288	11/26/2013	PowerPoint: "Namenda XR Report of Findings: Physicians & Caregivers"	802 and Hearsay within Hearsay	
DTX-287		FRX-AT-03793457	FRX-AT-03793457	1/3/2014	Excel: "Copy of Namenda production forecast_10292013_Flex XR LOE 112513.xlsx"		Yes
DTX-290		FRX-AT-03799130	FRX-AT-03799175	Feb-14	PowerPoint: "Corporate Overview"		
DTX-297	Lahman (Optum) Ex. 7	FRX-AT-03929811	FRX-AT-03929821	2/7/2014	Document: "Seventh (7th) Amendment to Medicare Part D Rebate Agreement Between OptumRx, Inc. and Forest Laboratories, Inc."		
DTX-298		FRX-AT-03941459	FRX-AT-003941510	1/24/2014	PowerPoint: "Namenda XR Report of Findings: Physicians & Caregivers & Long-term care professionals"	802 and Hearsay within Hearsay	
DTX-300	Cremieux Ex. 5 Snyder Ex. 8	FRX-AT-03983932	FRX-AT-03983935	1/14/2015	Email: "FW: Update from previous correspondence: Information about NAMENDA® (memantine HCl) tablets and NAMENDA XR® (memantine HCl) extended-release capsules"		
DTX-303		FRX-AT-04056937	FRX-AT-04056938	4/27/2015	Email: "FW: Namenda Online Caregiver Study-Key results highlights"	802 and Hearsay within Hearsay	
DTX-305		FRX-AT-04199437	FRX-AT-04199468	10/10/2013	Email: "NamendaTransitionPlan2"		
DTX-312	Cremieux Ex. 7 Snyder Ex. 10	FRX-AT-04287221	FRX-AT-04287222	1/13/2015	Press Release: "Important Information about NAMENDA (memantine HCl) tablets and NAMENDA XR (memantine HCl) extended-release capsules"		
DTX-339	Solomon Ex. 16	FRX-AT-04610859	FRX-AT-04611155	4/11/2014	Email: "RE: Namenda IR - Marketing plans and strategic/tactical plans"		
DTX-451	Doud (RDC) Ex. 7	RDC-NAM-003066	RDC-NAM-003067	12/12/2013	Email: "UPDATE - Pricing Report for PMC contract with Forest"	402, 403	
DTX-453	Doud (RDC) Ex. 16	RDC-NAM-010459	RDC-NAM-010461	2/11/2014	Email: "RE: Availability Update-NDC #0456-3407 Namenda XR 7mg 30ct"		
DTX-455	Benton (Smith Drug) Ex. 22	SDC-NAM-000039	SDC-NAM-000052	8/8/2014	Email: "Important Namenda Information From Forest Pharmaceuticals, Inc."		
DTX-459	Benton (Smith Drug) Ex. 18	SDC-NAM-001207	SDC-NAM-001208	10/9/2015	Email: "RE: Memantine 5mg/10mg (Texas Medicaid)"		
DTX-536	Benton (Smith Drug) Ex. 21	N/A	N/A	Jul-13	Document: The DrugSmith Newsletter		
DTX-646		FRX-AT-01829191	FRX-AT-01829192	1/31/2015	Presentation: "Namenda XR slides for Actavis Board Meeting February1 (2).ppt"	402, 403, 802	
DTX-647		FRX-AT-01829376	FRX-AT-01829389	5/4/2015	Presentation: "Performance Tracker"	402, 403, 802	
DTX-648		FRX-AT-01893950	FRX-AT-01893956	1/6/2015	Email: "FW: Attention Sales Force! Important Namenda XR information"		

1:15-cv-07488-CM-RWL

## Forest's Phase 2 Exhibit List

Trial Ex. No.	Dep. Ex. #	Beg Bates	End Bates	Date	Doc Description	Objections	Includes Electronic File(s)
DTX-649		FRX-AT-01894075	FRX-AT-01894075	2/12/2015	Document: "NAMENDA XR & NAMZARIC.ppt"	402, 403, 802	
DTX-650		FRX-AT-01894114	FRX-AT-01894117	2/20/2015	Presentation: "Namenda Conversion Metrics 2-20.ppt"		
DTX-651		FRX-AT-01894436	FRX-AT-01894453	4/1/2015	Presentation: "Franchise Update 4-3-15 with 2 scenarios extra.ppt"		
DTX-654		FRX-AT-03576395	FRX-AT-03576396	5/4/2015	Document: "CY15 Namenda Marketing Plans one page.doc"		
DTX-655		FRX-AT-03695050	FRX-AT-03695098	3/3/2015	Email: "Actavis Investor Day Transcript"	802	
DTX-656		FRX-AT-03695894	FRX-AT-03695904	5/26/2015	Email: "FW: Namenda XR Weekly NTB tracker w.e. 05-15-15"		
DTX-657		FRX-AT-03743524	FRX-AT-03743527	1/5/2015	Email: "RE: NAMENDA XR DTC campaign LAUNCHES TOMORROW"		
DTX-658		FRX-AT-03744297	FRX-AT-03744337	1/14/2015	Email: "RE: Namenda 2015 Digital Media Follow Up"	802	
DTX-659		FRX-AT-03745523	FRX-AT-03745526	2/6/2015	Email: "Namenda Weekly Performance Report - w.e. 1/30/15"		Yes
DTX-661		FRX-AT-03747277	FRX-AT-03747284	3/16/2015	Email: "Namenda XR Weekly NTB Tracker w.e. 03-06-15"		
DTX-663	Cremieux Ex. 9 Fowdur Ex. 24	FRX-AT-03749306	FRX-AT-03749308	5/1/2015	Email: "FW:Namenda Email Program Reporting (thru 6/15)"		Yes
DTX-667		FRX-AT-03751921	FRX-AT-03751937	7/8/2015	Email: "DTC ROI"	402, 403, 802	
DTX-684		FRX-AT-04275693	FRX-AT-04275698	11/20/2014	Email: "RE: Connecting on news"	802	
DTX-685		FRX-AT-04288455	FRX-AT-04288485	1/13/2015	Email: "FW: Final Communications/Websites"		
DTX-697		FRX-AT-04390632	FRX-AT-04390675	7/27/2011	Email: "Forest Story Deck and Speaking Points"	802, HS w/in HS, 402	
DTX-698		FRX-AT-03570688	FRX-AT-03570698	10/2/2014	Email: "Namenda Source of Business Report - August 2014"		
DTX-699		FRX-AT-04052783	FRX-AT-04052792	1/8/2015	Email: "Namenda Source of Business - Nov 2014"		
DTX-724		FRX-AT-01808512	FRX-AT-01808513	6/10/2014	Email: "FieldcommunicationJun10.doc"		
DTX-732		FRX-AT-03745849	FRX-AT-03745852	2/17/2015	Email: "RE: Actavis 'Unconditional Love' Media Tour Audience Report - 2.17.15"	802	
DTX-734		FRX-AT-03748185	FRX-AT-03748188	4/3/2015	Email: "Namenda Weekly Performance Tracker - w.e. 03-27-15"		Yes
DTX-735		FRX-AT-03752216	FRX-AT-03752224	7/27/2015	Email: "Namenda XR Weekly NTB tracker w.e. 07-17-15"		
DTX-737		FRX-AT-03791276	FRX-AT-03791277	9/1/2014	Email: "Re: Namenda XR FAQs"		
DTX-739		FRX-AT-03796969	FRX-AT-03796977	4/21/2015	Email: "Namenda XR Weekly NTB Tracker w.e. 04-10-15"		
DTX-744		FRX-AT-03910611	FRX-AT-03910631	3/9/2015	Email: "Actavis_Weekly Portfolio Tracker w.e. 02/27/15"		
DTX-747		FRX-AT-04055270	FRX-AT-04055278	2/17/2015	Email: "FW: Namenda XR Weekly NTB Tracker - w.e. 02-06-15"		
DTX-748		FRX-AT-04055476	FRX-AT-04055479	2/23/2015	Email: "Look at these graphs! Great momentum!"		
DTX-756		FRX-AT-03753834	FRX-AT-3753837	8/21/2015	Email: "Namenda Franchise Weekly Update"		
DTX-759		FRX-AT-03744744	FRX-AT-03744746	1/21/2015	Email: "FW: benchmark again linzess"		Yes
DTX-762		FRX-AT-04055584	FRX-AT-04055592	2/24/2015	Email: "for 2:30pm discussion"	402, 403, 802	
DTX-764		FRX-AT-03747125	FRX-AT-03747147	3/11/2015	Email: "RE: Link for Namenda XR ad"	802	
DTX-770		FRX-AT-03750895	FRX-AT-03750904	6/15/2015	Email: "Namenda Weekly NTB Tracker w.e. 06-05-15"		
DTX-771		FRX-AT-03752113	FRX-AT-03752116	7/17/2015	Email: "Namenda Weekly Performance Report w.e. 07-10-15"		Yes

1:15-cv-07488-CM-RWL

## Forest's Phase 2 Exhibit List

Trial Ex. No.	Dep. Ex. #	Beg Bates	End Bates	Date	Doc Description	Objections	Includes Electronic File(s)
DTX-772		FRX-AT-03749618	FRX-AT-03749621	5/8/2015	Email: "Namenda Weekly Performance Report w.e. 05-01-15"		
DTX-773		FRX-AT-03750886	FRX-AT-03750889	6/12/2015	Email: "Namenda Weekly Performance Report w.e. 6-5-15"		Yes